SHTDY SINOPHARM GROUP CO
- 14.370
- -0.120-0.83%
SINOPHARM GROUP CO News
China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status
China Traditional Chinese Medicine Holdings (HKG:0570) and Sinopharm Common Wealth jointly announced that Sinopharm's representatives have been preparing required documents, notifications, filings and
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Sinopharm Holdings (01099.HK) was reduced by 1.171 million shares by J.P. Morgan
Glonghui, May 9 | According to the latest equity disclosure data on the Stock Exchange, on May 2, 2024, Sinopharm Holdings (01099.HK) was reduced by JPMorgan Chase & Co. from a good position of 1.171 million shares at an average price of HK$19.4312 per share, involving an investment of about HK$22.754 million. After the reduction in holdings, JPMorgan Chase & Co.'s latest number of open positions was 798.571 million shares, and the holding ratio dropped from 6.03% to 5.95%.
Xiaomo reduced its holdings of Sinopharm Holdings (01099) by about 1.171 million shares at a price of about HK$19.43 per share
On May 2, Xiaomo reduced its holdings of Sinopharm Holdings (01099) by 1,1709.97 million shares, at a price of HK$19.4312 per share, for a total amount of about HK$22.7539 million.
J.P. Morgan sold 1.171 million common shares of Sinopharm Holdings (01099.HK) worth approximately HK$22.753,900
On May 8, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 8, JPMorgan Chase & Co. (JPMorgan Chase & Co.) sold $1.171,000 common shares worth HK$22.7539 million on May 2 at an average market price of HK$19.4312 and an average OTC share price of HK$19.4642. After the sale, J.P. Morgan Chase's latest shareholding was 798.571 million shares, and the good position ratio dropped from 6.03% to 5.95%. Photo source: Stock Exchange share disclosure what is a right
Xiaoma increased its holdings of Sinopharm Holdings (01099) by about 1,327 million shares at a price of about HK$20.01 per share
On April 30, Xiaomo increased its holdings of Sinopharm Holdings (01099) by 1,3269.95 million shares, at a price of HK$20.0142 per share, for a total amount of about HK$26.5587 million.
Sinopharm Holdings (01099.HK) received 1.377 million shares from J.P. Morgan Chase
Gelonghui, May 8 | According to the latest equity disclosure data from the Stock Exchange, on April 30, 2024, Sinopharm Holdings (01099.HK) obtained JPMorgan Chase & Co. increased its position by 1.37,000 shares at an average price of HK$20.0142 per share, involving approximately HK$26.559 million. After the increase in holdings, JPMorgan Chase & Co.'s latest number of positions was 81.0281 million shares, and the holding ratio increased from 5.93% to 6.03%.
Sinopharm Holdings (01099.HK) received an increase of 1,327,000 H shares from J.P. Morgan Chase, worth approximately HK$26.5587 million
On May 7, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 7, JPMorgan Chase & Co. (JPMorgan Chase & Co.) increased its holdings of $Sinopharm Holdings (01099.HK) by $1,327,000 on April 30, with an average price of HK$20.0142 per share and an average OTC share price of HK$19.9864, to a total value of HK$26.5587 million. After the increase in holdings, the latest number of shares held by J.P. Morgan Chase was 81.281 million shares, and the good position ratio increased from 5.93% to 6.03%. Photo source: Stock Exchange share disclosure what is a right
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Sinopharm Holdings (01099.HK): Main business maintains growth trend, transformation and innovation continue to advance
Revenue for the first quarter of 2024 was in line with our expectations, and net profit was slightly lower than our expectations. The company announced the results for the first quarter of 2024: revenue of RMB 147.27 billion, an increase of 1.2% over the previous year, and net profit attributable to the parent company RMB
Sinopharm Holdings (01099) plans to uniformly register and issue 30 billion yuan of non-financial corporate debt financing instruments in China
Sinopharm Holdings (01099) announced that in order to meet the company's actual needs for supplementary operation and provision of capital, it guarantees direct financing channels...
Sinopharm Group 1Q Total Operating Revenue CNY147.27B Vs. CNY145.52B >1099.HK
Sinopharm Group 1Q Total Operating Revenue CNY147.27B Vs. CNY145.52B >1099.HK
Sinopharm Holdings (01099) announced first-quarter results, net profit of about 1.42 billion yuan, a year-on-year decrease of 10.7%
Sinopharm Holdings (01099) announced its results for the first quarter of 2024, with total revenue of about 147.266 billion yuan,...
國藥控股：公告 截至 2024 年 3 月 31 日止三個月之季度財務資料
國藥控股：年度報告2023
國藥控股：公告 國藥股份截至2024年3月31日止第一季度之 主要未經審核會計數據和財務指標
Sinopharm Holdings (01099): Sinopharm (000028.SZ) net profit of about 389 million yuan in the first quarter increased 7.33% year-on-year
Sinopharm Holdings (01099) announced Sinopharm's (000028.SZ) results for the first quarter of 2024, operating...
國藥控股：公告 國藥一致截至2024年3月31日止第一季度之 主要未經審核會計數據和財務指標
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
Analysis
Price Target
No Data
